Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

Alicia C. McDonald, Manish Vira, Jing Shen, Martin Sanda, Jay D. Raman, Jason Liao, Dattatraya Patil, Emanuela Taioli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: MicroRNAs (miRNAs) have been linked to prostate cancer (PC) risk; however, their role as a screening biomarker for PC has yet to be determined. We examined whether circulating miRNAs in plasma could be potential biomarkers for the early detection of PC among men undergoing prostate needle biopsy. Methods: Men who had a prostate biopsy due to an abnormal screening test were recruited. Linear regression was used to examine the association between miRNAs in plasma and PC status and to model individual miRNA expression on serum PSA and age to calculate the partial correlation coefficient (r). Results: There were 134 men, aged 46-86 years, included, with 66 men with a PC diagnosis (cases), eight men with no PC diagnosis but atypical lesion, and 60 men without a PC diagnosis (controls). The most statistically significant PC circulating miRNAs were miR-381, miR-34a, miR-523, miR-365, miR-122, miR-375, miR-1255b, miR-34b, miR-450b-5p, and miR-639 after adjusting for age (P-values ≤0.05); however, they were no longer statistically significant after P-value adjustment for multiple comparisons. MiR-671-3p was differentially expressed between black and white cases (P-value = 0.03). Moderate positive correlations with serum PSA were observed for miR-381 overall and among controls (r = 0.43-0.60; P-values ≤0.05) and miR-34a among cases (r = 0.46; P-value = 0.02). Conclusions: There was no miRNA associated with PC diagnosis after adjusting for age and P-values; however, moderate correlations between miRNAs and serum PSA were observed. Further investigation between miRNAs and PC risk is warranted in a larger population at high risk for PC.

Original languageEnglish (US)
Pages (from-to)411-418
Number of pages8
JournalProstate
Volume78
Issue number6
DOIs
StatePublished - May 1 2018

Fingerprint

MicroRNAs
Early Detection of Cancer
Prostatic Neoplasms
Biomarkers
Prostate
Serum
Needle Biopsy
Linear Models
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

McDonald, Alicia C. ; Vira, Manish ; Shen, Jing ; Sanda, Martin ; Raman, Jay D. ; Liao, Jason ; Patil, Dattatraya ; Taioli, Emanuela. / Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. In: Prostate. 2018 ; Vol. 78, No. 6. pp. 411-418.
@article{605981cf89c04d63b4b084ad18835411,
title = "Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer",
abstract = "Background: MicroRNAs (miRNAs) have been linked to prostate cancer (PC) risk; however, their role as a screening biomarker for PC has yet to be determined. We examined whether circulating miRNAs in plasma could be potential biomarkers for the early detection of PC among men undergoing prostate needle biopsy. Methods: Men who had a prostate biopsy due to an abnormal screening test were recruited. Linear regression was used to examine the association between miRNAs in plasma and PC status and to model individual miRNA expression on serum PSA and age to calculate the partial correlation coefficient (r). Results: There were 134 men, aged 46-86 years, included, with 66 men with a PC diagnosis (cases), eight men with no PC diagnosis but atypical lesion, and 60 men without a PC diagnosis (controls). The most statistically significant PC circulating miRNAs were miR-381, miR-34a, miR-523, miR-365, miR-122, miR-375, miR-1255b, miR-34b, miR-450b-5p, and miR-639 after adjusting for age (P-values ≤0.05); however, they were no longer statistically significant after P-value adjustment for multiple comparisons. MiR-671-3p was differentially expressed between black and white cases (P-value = 0.03). Moderate positive correlations with serum PSA were observed for miR-381 overall and among controls (r = 0.43-0.60; P-values ≤0.05) and miR-34a among cases (r = 0.46; P-value = 0.02). Conclusions: There was no miRNA associated with PC diagnosis after adjusting for age and P-values; however, moderate correlations between miRNAs and serum PSA were observed. Further investigation between miRNAs and PC risk is warranted in a larger population at high risk for PC.",
author = "McDonald, {Alicia C.} and Manish Vira and Jing Shen and Martin Sanda and Raman, {Jay D.} and Jason Liao and Dattatraya Patil and Emanuela Taioli",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/pros.23485",
language = "English (US)",
volume = "78",
pages = "411--418",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. / McDonald, Alicia C.; Vira, Manish; Shen, Jing; Sanda, Martin; Raman, Jay D.; Liao, Jason; Patil, Dattatraya; Taioli, Emanuela.

In: Prostate, Vol. 78, No. 6, 01.05.2018, p. 411-418.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer

AU - McDonald, Alicia C.

AU - Vira, Manish

AU - Shen, Jing

AU - Sanda, Martin

AU - Raman, Jay D.

AU - Liao, Jason

AU - Patil, Dattatraya

AU - Taioli, Emanuela

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: MicroRNAs (miRNAs) have been linked to prostate cancer (PC) risk; however, their role as a screening biomarker for PC has yet to be determined. We examined whether circulating miRNAs in plasma could be potential biomarkers for the early detection of PC among men undergoing prostate needle biopsy. Methods: Men who had a prostate biopsy due to an abnormal screening test were recruited. Linear regression was used to examine the association between miRNAs in plasma and PC status and to model individual miRNA expression on serum PSA and age to calculate the partial correlation coefficient (r). Results: There were 134 men, aged 46-86 years, included, with 66 men with a PC diagnosis (cases), eight men with no PC diagnosis but atypical lesion, and 60 men without a PC diagnosis (controls). The most statistically significant PC circulating miRNAs were miR-381, miR-34a, miR-523, miR-365, miR-122, miR-375, miR-1255b, miR-34b, miR-450b-5p, and miR-639 after adjusting for age (P-values ≤0.05); however, they were no longer statistically significant after P-value adjustment for multiple comparisons. MiR-671-3p was differentially expressed between black and white cases (P-value = 0.03). Moderate positive correlations with serum PSA were observed for miR-381 overall and among controls (r = 0.43-0.60; P-values ≤0.05) and miR-34a among cases (r = 0.46; P-value = 0.02). Conclusions: There was no miRNA associated with PC diagnosis after adjusting for age and P-values; however, moderate correlations between miRNAs and serum PSA were observed. Further investigation between miRNAs and PC risk is warranted in a larger population at high risk for PC.

AB - Background: MicroRNAs (miRNAs) have been linked to prostate cancer (PC) risk; however, their role as a screening biomarker for PC has yet to be determined. We examined whether circulating miRNAs in plasma could be potential biomarkers for the early detection of PC among men undergoing prostate needle biopsy. Methods: Men who had a prostate biopsy due to an abnormal screening test were recruited. Linear regression was used to examine the association between miRNAs in plasma and PC status and to model individual miRNA expression on serum PSA and age to calculate the partial correlation coefficient (r). Results: There were 134 men, aged 46-86 years, included, with 66 men with a PC diagnosis (cases), eight men with no PC diagnosis but atypical lesion, and 60 men without a PC diagnosis (controls). The most statistically significant PC circulating miRNAs were miR-381, miR-34a, miR-523, miR-365, miR-122, miR-375, miR-1255b, miR-34b, miR-450b-5p, and miR-639 after adjusting for age (P-values ≤0.05); however, they were no longer statistically significant after P-value adjustment for multiple comparisons. MiR-671-3p was differentially expressed between black and white cases (P-value = 0.03). Moderate positive correlations with serum PSA were observed for miR-381 overall and among controls (r = 0.43-0.60; P-values ≤0.05) and miR-34a among cases (r = 0.46; P-value = 0.02). Conclusions: There was no miRNA associated with PC diagnosis after adjusting for age and P-values; however, moderate correlations between miRNAs and serum PSA were observed. Further investigation between miRNAs and PC risk is warranted in a larger population at high risk for PC.

UR - http://www.scopus.com/inward/record.url?scp=85041207946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041207946&partnerID=8YFLogxK

U2 - 10.1002/pros.23485

DO - 10.1002/pros.23485

M3 - Article

C2 - 29383739

AN - SCOPUS:85041207946

VL - 78

SP - 411

EP - 418

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 6

ER -